肝细胞癌症(HCC)治疗药的全球市场的预测 - 流行病学，开发平台分析(2022年～2027年)

全球肝细胞癌症(HCC)治疗药的市场规模在2022年～2027年预计将以年复合成长率17.39％的速度成长。

本报告提供全球肝细胞癌症(HCC)治疗药市场相关调查分析，提供市场规模，流行病学，开发平台药物品，临床试验等资讯。

目录

第1章 肝细胞癌症(HCC)概要

• 肝细胞癌症(HCC) - 概要

第2章 肝细胞癌症(HCC)的流行病学和概要

• 主要8市场HCC的发生数和患病数的实际成果与预测
• 主要8市场HCC的发生率和盛行率的比较分析
• 主要8市场HCC的发生数和患病数的实际成果与预测:各年龄层
• 主要8市场HCC病例的发生率的比较分析:各年龄层
• 美国的HCC的发生数和患病数的实际成果与预测
• 美国的HCC的发生率和盛行率的比较分析
• 美国的HCC的发生数和患病数的实际成果与预测:各年龄层
• 美国的HCC病例的发生率的比较分析:各年龄层
• 中国的HCC的发生数和患病数的实际成果与预测
• 中国的HCC的发生率和盛行率的比较分析
• 中国的HCC的发生数和患病数的实际成果与预测:各年龄层
• 中国的HCC病例的发生率的比较分析:各年龄层
• 日本的HCC的发生数和患病数的实际成果与预测
• 日本的HCC的发生率和盛行率的比较分析
• 日本的HCC的发生数和患病数的实际成果与预测:各年龄层
• 日本的HCC病例的发生率的比较分析:各年龄层
• 德国的HCC的发生数和患病数的实际成果与预测
• 德国的HCC的发生率和盛行率的比较分析
• 德国的HCC的发生数和患病数的实际成果与预测:各年龄层
• 德国的HCC病例的发生率的比较分析:各年龄层
• 英国的HCC的发生数和患病数的实际成果与预测
• 英国的HCC的发生率和盛行率的比较分析
• 英国的HCC的发生数和患病数的实际成果与预测:各年龄层
• 英国的HCC病例的发生率的比较分析:各年龄层
• 法国的HCC的发生数和患病数的实际成果与预测
• 法国的HCC的发生率和盛行率的比较分析
• 法国的HCC的发生数和患病数的实际成果与预测:各年龄层
• 法国的HCC病例的发生率的比较分析:各年龄层
• 义大利的HCC的发生数和患病数的实际成果与预测
• 义大利的HCC的发生率和盛行率的比较分析
• 义大利的HCC的发生数和患病数的实际成果与预测:各年龄层
• 义大利的HCC病例的发生率的比较分析:各年龄层
• 西班牙的HCC的发生数和患病数的实际成果与预测
• 西班牙的HCC的发生率和盛行率的比较分析
• 西班牙的HCC的发生数和患病数的实际成果与预测:各年龄层
• 西班牙的HCC病例的发生率的比较分析:各年龄层

第3章 肝细胞癌症(HCC)的市场规模和概要

• 主要8市场HCC的实际成果与预测的收益
• 主要8市场HCC的实际成果与预测的收益的概述
• 主要8市场的实际成果与预测的收益:性别，各年龄层，各级药品
• 美国的HCC的实际成果与预测的收益
• 美国的HCC的实际成果与预测的收益的概述
• 美国的实际成果与预测的收益:性别，各年龄层，各级药品
• 中国的HCC的实际成果与预测的收益
• 中国的HCC的实际成果与预测的收益的概述
• 中国的实际成果与预测的收益:性别，各年龄层，各级药品
• 日本的HCC的实际成果与预测的收益
• 日本的HCC的实际成果与预测的收益的概述
• 日本的实际成果与预测的收益:性别，各年龄层，各级药品
• 德国的HCC的实际成果与预测的收益
• 德国的HCC的实际成果与预测的收益的概述
• 德国的实际成果与预测的收益:性别，各年龄层，各级药品
• 英国的HCC的实际成果与预测的收益
• 英国的HCC的实际成果与预测的收益的概述
• 英国的实际成果与预测的收益:性别，各年龄层，各级药品
• 法国的HCC的实际成果与预测的收益
• 法国的HCC的实际成果与预测的收益的概述
• 法国的实际成果与预测的收益:性别，各年龄层，各级药品
• 义大利的HCC的实际成果与预测的收益
• 义大利的HCC的实际成果与预测的收益的概述
• 义大利的实际成果与预测的收益:性别，各年龄层，各级药品
• 西班牙的HCC的实际成果与预测的收益
• 西班牙的HCC的实际成果与预测的收益的概述
• 西班牙的实际成果与预测的收益:性别，各年龄层，各级药品

第4章 肝细胞癌症(HCC)的已上市药品概要

• 肝细胞癌症(HCC)的已上市药品 - 概要
• 肝细胞癌症(HCC)的已上市药品 - 摘要

第5章 肝细胞癌症(HCC)的开发平台药物品概要

• HCC开发平台药物品 - 概要
• HCC开发平台药物品 - 概述
• 开发平台药物品的概要与概述 - 各疾病类型
• HCC开发平台药物品的概要与概述 - 各开发阶段
• HCC开发平台药物品的概要与概述 - 各给药途径
• HCC开发平台药物品的概要与概述 - 各作用机制
• HCC开发平台药物品的概要与概述 - 各分子类型
• HCC开发平台药物品的概要与概述 - 各地区类型

第6章 肝细胞癌症(HCC)的临床试验概要

• HCC临床试验概要的概述
• HCC临床试验概要 - 募集情况
• HCC临床试验概要 - 各产品类型
• HCC临床试验概要 - 各给药途径
• HCC临床试验概要 - 各分子类型
• HCC临床试验概要 - 各地区类型

第7章 肝细胞癌症(HCC)的市场动态

• HCC治疗药市场促进因素
• HCC治疗药市场阻碍因素
• HCC治疗药市场趋势

第8章 肝细胞癌症(HCC)的竞争情形

• HCC的竞争情形情形 - 已上市药品
• 主要企业简介
• 其他的主要企业简介
• HCC治疗药市场竞争模式
• 主要企业概要
• 肝细胞癌症(HCC)的竞争情形 - 开发平台药物品
• 主要的新兴企业的简介
• 其他的主要的新兴企业的简介
• 主要企业概要

第9章 肝细胞癌症(HCC)的其他

• 主要的临时性的医药品核准的时间轴
• 主要的法规指定
• 主要的里程碑
• 交易和合作
• 非活性/生产结束/暂停中的产品
• 未满足需求/策略性推荐事项

第10章 附录

The global hepatocellular carcinoma treatment market is expected to grow at a CAGR of 17.39% during 2022-2027.

MARKET OUTLOOK

Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. HCC is particularly aggressive and has a poor survival rate (five-year survival <5%) and therefore remains a significant public health issue worldwide. In Asia and Africa, factors for development include Hepatitis B and C infection, aflatoxin exposure, liver cirrhosis, and hemochromatosis. In contrast, in developed countries, factors for developing HCC include diabetes, obesity, and non-alcoholic steatohepatitis (NASH). According to published studies, liver cancer is a leading cause of cancer death worldwide, accounting for more than 800,000 deaths and 900,000 new cases yearly.

Arizton estimates that the prevalence of hepatocellular carcinoma will be high in China, followed by the US and Japan in 2020. The increasing prevalence of HCC is driving the hepatocellular carcinoma treatment market growth. According to estimates, more than 1 million people will be affected with hepatocellular carcinoma annually by 2025.

Hepatocellular Carcinoma Therapeutics: Pipeline Scenario

The global hepatocellular carcinoma treatment market portfolio contains a total of 155+ assets in various development phases. Most industry-sponsored drugs in active clinical development for HCC are in the Phase II stage. Anti-PD-1 and PD-L1 monoclonal antibodies are dominating the Hepatocellular Carcinoma drug pipeline.

Hepatocellular Carcinoma Therapeutics: Clinical Trials Scenario

The clinical trial portfolio of the hepatocellular carcinoma treatment market contains 220+ trials in various development phases. Most industry-sponsored drugs in active clinical development for hepatocellular carcinoma are in the Phase II stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for hepatocellular carcinoma have been in the early and mid-phases of development, with 55-60% of trials in Phase I-II and only 40% in Phase III-IV. The US has a substantial lead in the number of hepatocellular carcinoma clinical trials globally.

MARKET TRENDS & DRIVERS

Increasing Adoption for Biological Therapies

• Biological therapies such as immune-targeted therapies (Immunotherapies) are widely used to treat hepatocellular carcinoma. With Nivolumab being the biologic approved for hepatocellular carcinoma in 2017, there is a demand for therapies with novel MOAs. Many new classes of therapies are looking to enter the global hepatocellular carcinoma treatment market over the next few years. The biologics such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) make inroads into the hepatocellular carcinoma market owing to their better clinical profile.

Anticipated Launch of Emerging Drugs

• A recent wave of biologic products prescribed for treating HCC is likely to create a lucrative opportunity for hepatocellular carcinoma (HCC) treatment market growth. Despite the plethora of therapies currently available to patients with hepatocellular carcinoma (HCC), there is still room for improvement within the treatment space. Arizton anticipates the launch of five new agents among the 8MM, including three programmed cell death 1 (PD-1) inhibitors (Camrelizumab, Tislelizumab, and Cemiplimab), one programmed cell death ligand 1 (PD-L1) inhibitor (Durvalumab) and one Lymphocyte-activation gene (LAG-3) inhibitor (Relatlimab). Launching these late-stage drugs will create an opportunity for the AD market growth.

Focus on Novel Drugs with Novel Mechanism

• The therapeutic agents targeting PD-1 and PD-L1 have been proven to be very effective in HCC, some are already in the therapeutic armamentarium, and others are in development. Over the next five years, Arizton expects to see a surge of innovation emerging from the research and development pipeline and a range of technology-enabled transformations that will expand the evidence-basis for interventions and bring measurable improvements to outcomes.

INSIGHTS BY DRUG CLASS

Chemotherapeutic drugs are expected to dominate the global HCC therapeutics market among the drug class. However, the targeted therapies are expected to be the fastest-growing segment during the forecast period. Recently approved biologics such as Tecentriq (Atezolizumab) are expected to drive the global hepatocellular carcinoma treatment market from 2022-2027. The HCC industry has historically relied on chemotherapies that have been available for over a decade. But recent developments have led to research on novel mechanisms of action (MOAs) to combat the high numbers of patients experiencing treatment non-response. The hepatocellular carcinoma treatment market will experience significant growth due mainly to the launch of new drugs, most of which are expected to launch between 2023-2026, targeting the moderate-to-severe patient population. The biologics such as anti-PD-1 and PD-L1 inhibitors are making inroads into the HCC market owing to their better clinical profile.

Segmentation by Drug Class

• Chemotherapy
• Targeted Therapy

INSIGHTS BY GENDER TYPE

Among the gender type, men were expected to account for a significant share of the global hepatocellular carcinoma treatment market based on gender type. This is because of more likely men predominance over women.

Segmentation by Gender Type

• Men
• Women

INSIGHTS BY AGE GROUP

The global hepatocellular carcinoma treatment market based on age group is dominated by the 50 yrs & above age group segment. The disease can occur at any age, but HCC is most often diagnosed in adolescents and adults between 50 and 65.

Segmentation by Age Group

• Below 29 years
• 30-49 years
• 50+ years

GEOGRAPHICAL ANALYSIS

The US dominates the global hepatocellular carcinoma treatment market by geography due to the healthcare affordability in the US, the knowledge and awareness amongst the people, and the technological advancement in this region. However, China is expected to grow faster with a high CAGR in the HCC drug market due to the rise in access and quality of healthcare, increased awareness about disease management, and rising healthcare expenditure in this region. Among 8MM, the US accounts for a significant market share of 48.07%, with a CAGR of 19.33% in the hepatocellular carcinoma treatment market.

Segmentation by Geography

• North America
  • US
• APAC
  • China
  • Japan
• Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain

VENDOR LANDSCAPE

The global hepatocellular carcinoma treatment market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating hepatocellular carcinoma. The U.S. Food and Drug Administration (FDA) approved the Anti PD-1 monoclonal antibody Nivolumab (Opdivo) for treating HCC in 2017. Following this, the FDA approved Keytruda (pembrolizumab) in 2018 and Tecentriq (atezolizumab) in 2020 for treating HCC. Although generic products continue to capture significant hepatocellular carcinoma treatment market share, the arrival of biologics and other targeted therapies indicate a paradigm shift in this therapeutic space through the forecast period.

The hepatocellular carcinoma portfolio contains a total of 155+ assets in various development phases. The emerging therapeutics being developed for hepatocellular carcinoma include Camrelizumab, Tislelizumab, Cemiplimab, CS-1003, Relatlimab, and others. Launching these novel emerging drugs will shift the hepatocellular carcinoma treatment paradigm in the near future. With more than 155+ molecules in various stages of development, it is expected that new vendors are likely to enter the market with novel mechanisms of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating HCC.

The prominent players offering drugs in the global hepatocellular carcinoma treatment market includes Roche, Bayer, Merck & Co., Bristol-Myers Squibb, Exelixis Inc, Eli Lilly and Company, Innovent Biologics, AstraZeneca, BeiGene, Jiangsu HenGrui Medicine, and many others. These players are focused on R&D initiatives for developing technologically advanced and innovative HCC drugs and are also entering into collaborations to maintain their position in the market. These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs to compete in the global HCC therapeutics market.

Key Vendors

• Merck & Co.
• Bayer
• Roche
• Eli Lilly and Company
• Bristol-Myers Squibb
• Exelixis Inc (Exelixis)
• Innovent Biologics Inc
• Akeso, Inc
• Jiangsu Hengrui Medicine Co Ltd
• AstraZeneca Plc
• BeiGene
• Sanofi SA

Other Prominent Vendors

• Shenzhou Cell
• Yiviva
• Surface Oncology
• Advenchen Laboratories, LLC
• Abbisko Therapeutics
• Shanghai Henlius Biotech
• Novra Technologies Inc
• TaiRx, Inc.
• Zelgen Biopharmaceuticals
• Pfizer
• Virogin Biotech
• Genoscience

Key Milestones In The Hepatocellular Carcinoma Treatment Market :

• In November 2018, Merck & Co., Inc. announced that the Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib. The approval was based on KEYNOTE 224 (NCT02702414), a single-arm, multicenter trial enrolling 104 patients with hepatocellular carcinoma.
• In May 2020, Roche announced that the Food and Drug Administration approved atezolizumab in combination with bevacizumab (Tecentriq) for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy. The approval is based on IMbrave150 (NCT03434379), a multicenter, international, open-label, randomized trial in patients with locally advanced unresectable or metastatic hepatocellular carcinoma who had not received prior systemic therapy.
• In May 2019, Eli Lilly and Company announced that the Food and Drug Administration approved ramucirumab (Cyramza) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha-fetoprotein (AFP) of ≥ 400 ng/mL and have been previously treated with sorafenib. The approval was based on REACH 2 (NCT02435433), a multinational, randomized, double-blind, placebo-controlled, multicenter study in 292 patients with advanced HCC with AFP ≥ 400 ng/mL who had disease progression on or after sorafenib or who were intolerant.

Key Mergers & Acquisitions In The Hepatocellular Carcinoma Treatment Market:

• In Jun 2018, Blueprint Medicines Corporation and CStone Pharmaceuticals announced an exclusive collaboration and license agreement for the development and commercialization of avapritinib, BLU-554, and BLU-667 in Mainland China, Hong Kong, Macau, and Taiwan, either as monotherapies or combination therapies.
• In Dec 2016, Exelixis Inc. and Ipsen announced an amendment to the exclusive collaboration and licensing agreement for cabozantinib's commercialization and continued development. It is included in the commercialization rights in Canada. Under the terms of the amendment, Exelixis will receive a USD 10 million upfront payment. Exelixis is eligible to receive regulatory milestones for the approvals of cabozantinib in Canada for advanced renal cell carcinoma (RCC) after prior treatment, for first-line RCC, and advanced hepatocellular carcinoma (HCC), as well as additional regulatory milestones for potential further indications.

REPORT COVERS

a) Detailed overview of hepatocellular carcinoma (HCC) treatment market, including disease definition, classification, diagnosis, and treatment pattern

b) Overview of the global trends of HCC in the eight major markets (8MM)

c) Historical, current, and projected patient pool of HCC in the eight major markets (8MM) for the 2018 - 2027 period

d) Gender type, Disease Type, Age Group, Drug Class, and Geography type segmentations of HCC in the eight major markets (8MM)

e) In-depth analysis of the market segments, which includes products, treatment, and competitor analysis

f) Global hepatocellular carcinoma treatment market share of the industry players, company profiles, product specifications, and competitive landscape

g) Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints

h) Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities

i) Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for hepatocellular carcinoma across the complete product development cycle, including all clinical and non-clinical stages

j) Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and geography type for hepatocellular carcinoma across all clinical stages

k) Coverage of dormant and discontinued pipeline projects along with the reasons across the hepatocellular carcinoma therapeutics market

l) Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the HCC space

KEY QUESTIONS ANSWERED

• 1. How big is the hepatocellular carcinoma treatment market?
• 2. What is the growth rate of the hepatocellular carcinoma treatment market?
• 3. Who are the key players in the global hepatocellular carcinoma treatment market
• 4. Which region holds the largest global hepatocellular carcinoma treatment market share?
• 5. What are the latest trends in the hepatocellular carcinoma treatment market?

TABLE OF CONTENTS

• 1. HEPATOCELLULAR CARCINOMA OVERVIEW
• 1.1. Hepatocellular Carcinoma (HCC) - An Overview
• 2. HEPATOCELLULAR CARCINOMA EPIDEMIOLOGY & OVERVIEW
• 2.1. 8MM: Historic & Projected Volume of Incidence & Prevalence of HCC
• 2.2. 8MM: Comparative Analysis of Incidence & Prevalence of HCC
• 2.3. 8MM: Historic & Projected Volume of Incidence of HCC cases by Age Group
• 2.4. 8MM: Comparative Analysis of Incidence of HCC cases by Age Group
• 2.5. US: Historic & Projected Volume of Incidence & Prevalence of HCC
• 2.6. US: Comparative Analysis of Incidence & Prevalence of HCC
• 2.7. US: Historic & Projected Volume of Incidence of HCC cases by Age Group
• 2.8. US: Comparative Analysis of Incidence of HCC cases by Age Group
• 2.9. China: Historic & Projected Volume of Incidence & Prevalence of HCC
• 2.10. China: Comparative Analysis of Incidence & Prevalence of HCC
• 2.11. China: Historic & Projected Volume of Incidence of HCC cases by Age Group
• 2.12. China: Comparative Analysis of Incidence of HCC cases by Age Group
• 2.13. Japan: Historic & Projected Volume of Incidence & Prevalence of HCC
• 2.14. Japan: Comparative Analysis of Incidence & Prevalence of HCC
• 2.15. Japan: Historic & Projected Volume of Incidence of HCC cases by Age Group
• 2.16. Japan: Comparative Analysis of Incidence of HCC cases by Age Group
• 2.17. Germany: Historic & Projected Volume of Incidence & Prevalence of HCC
• 2.18. Germany: Comparative Analysis of Incidence & Prevalence of HCC
• 2.19. Germany: Historic & Projected Volume of Incidence of HCC cases by Age Group
• 2.20. Germany: Comparative Analysis of Incidence of HCC cases by Age Group
• 2.21. UK: Historic & Projected Volume of Incidence & Prevalence of HCC
• 2.22. UK: Comparative Analysis of Incidence & Prevalence of HCC
• 2.23. UK: Historic & Projected Volume of Incidence of HCC cases by Age Group
• 2.24. UK: Comparative Analysis of Incidence of HCC cases by Age Group
• 2.25. France: Historic & Projected Volume of Incidence & Prevalence of HCC
• 2.26. France: Comparative Analysis of Incidence & Prevalence of HCC
• 2.27. France: Historic & Projected Volume of Incidence of HCC cases by Age Group
• 2.28. France: Comparative Analysis of Incidence of HCC cases by Age Group
• 2.29. Italy: Historic & Projected Volume of Incidence & Prevalence of HCC
• 2.30. Italy: Comparative Analysis of Incidence & Prevalence of HCC
• 2.31. Italy: Historic & Projected Volume of Incidence of HCC cases by Age Group
• 2.32. Italy: Comparative Analysis of Incidence of HCC cases by Age Group
• 2.33. Spain: Historic & Projected Volume of Incidence & Prevalence of HCC
• 2.34. Spain: Comparative Analysis of Incidence & Prevalence of HCC
• 2.35. Spain: Historic & Projected Volume of Incidence of HCC cases by Age Group
• 2.36. Spain: Comparative Analysis of Incidence of HCC cases by Age Group
• 3. HEPATOCELLULAR CARCINOMA MARKET SIZE & OVERVIEW
• 3.1. 8MM: Historic & Projected Revenue of HCC
• 3.2. 8MM: Historic & Projected Revenue of HCC Snapshot
• 3.3. 8MM: Historic & Projected Revenue Segmentation by Gender Type, Age Group & Drug Class
• 3.4. US: Historic & Projected Revenue of HCC
• 3.5. US: Historic & Projected Revenue of HCC Snapshot
• 3.6. US: Historic & Projected Revenue Segmentation by Gender Type, Age Group & Drug Class
• 3.7. China: Historic & Projected Revenue of HCC
• 3.8. China: Historic & Projected Revenue of HCC Snapshot
• 3.9. China: Historic & Projected Revenue Segmentation by Gender Type, Age Group & Drug Class
• 3.10. Japan: Historic & Projected Revenue of HCC
• 3.11. Japan: Historic & Projected Revenue of HCC Snapshot
• 3.12. Japan: Historic & Projected Revenue Segmentation by Gender Type, Age Group & Drug Class
• 3.13. Germany: Historic & Projected Revenue of HCC
• 3.14. Germany: Historic & Projected Revenue of HCC Snapshot
• 3.15. Germany: Historic & Projected Revenue Segmentation by Gender Type, Age Group & Drug Class
• 3.16. UK: Historic & Projected Revenue of HCC
• 3.17. UK: Historic & Projected Revenue of HCC Snapshot
• 3.18. UK: Historic & Projected Revenue Segmentation by Gender Type, Age Group & Drug Class
• 3.19. France: Historic & Projected Revenue of HCC
• 3.20. France: Historic & Projected Revenue of HCC Snapshot
• 3.21. France: Historic & Projected Revenue Segmentation by Gender Type, Age Group & Drug Class
• 3.22. Italy: Historic & Projected Revenue of HCC
• 3.23. Italy: Historic & Projected Revenue of HCC Snapshot
• 3.24. Italy: Historic & Projected Revenue Segmentation by Gender Type, Age Group & Drug Class
• 3.25. Spain: Historic & Projected Revenue of HCC
• 3.26. Spain: Historic & Projected Revenue of HCC Snapshot
• 3.27. Spain: Historic & Projected Revenue Segmentation by Gender Type, Age Group & Drug Class
• 4. HEPATOCELLULAR CARCINOMA MARKETED DRUGS OVERVIEW
• 4.1. Hepatocellular Carcinoma Marketed Drugs - An Overview
• 4.2. Hepatocellular Carcinoma Marketed Drugs - Summary
• 5. HEPATOCELLULAR CARCINOMA PIPELINE DRUGS OVERVIEW
• 5.1. HCC Pipeline Drugs - An Overview
• 5.2. HCC Pipeline Drugs - Snapshot
• 5.3. Pipeline Drugs Overview & Snapshot - By Disease type
• 5.4. HCC Pipeline Drugs Overview & Snapshot - By Development Phase
• 5.5. HCC Pipeline Drugs Overview & Snapshot - By Route of Administration
• 5.6. HCC Pipeline Drugs Overview & Snapshot - By Mechanism of Action
• 5.7. HCC Pipeline Drugs Overview & Snapshot - By Molecule type
• 5.8. HCC Pipeline Drugs Overview & Snapshot - By Geography type
• 6. HEPATOCELLULAR CARCINOMA CLINICAL TRIALS OVERVIEW
• 6.1. HCC Clinical Trials Overview Snapshot
• 6.2. HCC Clinical Trials Overview - By Recruitment Status
• 6.3. HCC Clinical Trials Overview - By Product type
• 6.4. HCC Clinical Trials Overview - By Route of Administration
• 6.5. HCC Clinical Trials Overview - By Molecule type
• 6.6. HCC Clinical Trials Overview - By Geography type
• 7. HEPATOCELLULAR CARCINOMA MARKET DYNAMICS
• 7.1. HCC Therapeutics Market Drivers
• 7.2. HCC Therapeutics Market Constraints
• 7.3. HCC Therapeutics Market Trends
• 8. HEPATOCELLULAR CARCINOMA COMPETITIVE LANDSCAPE
• 8.1. HCC Competitive Landscape - Marketed Drugs
• 8.2. Key Company Profiles
• 8.3. Other Key Company Profiles
• 8.4. Competitive Scenario of HCC therapeutics market
• 8.5. Key Company Overviews
• 8.6. Hepatocellular Carcinoma Competitive Landscape - Pipeline Drugs
• 8.7. Key Emerging Company Profiles
• 8.8. Other Key Emerging Company Profiles
• 8.9. Key Company Overviews
• 9. HEPATOCELLULAR CARCINOMA MISCELLANEOUS
• 9.1. Key Tentative Drug Approvals Timeline
• 9.2. Key Regulatory Designations
• 9.3. Key Milestones
• 9.4. Deals & Collaborations
• 9.5. Inactive/Discontinued/Dormant Products
• 9.6. Unmet needs/Strategic Recommendations
• 10. APPENDIX
• 10.1. About Arizton
• 10.2. Research Methodology
• 10.3. List of Abbreviations

LIST OF EXHIBITS

Exhibit 1: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 2: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN 8 MAJOR MARKETS (2018 - 2020)

Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 4: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 5: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN 8 MAJOR MARKETS (2018 - 2020)

Exhibit 6: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 7: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN US (2018 - 2027)

Exhibit 8: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN US (2018 - 2020)

Exhibit 9: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN US (2021 - 2027)

Exhibit 10: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN US (2018 - 2027)

Exhibit 11: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN US (2018 - 2020)

Exhibit 12: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN US (2021 - 2027)

Exhibit 13: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN CHINA (2018 - 2027)

Exhibit 14: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN CHINA (2018 - 2020)

Exhibit 15: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN CHINA (2021 - 2027)

Exhibit 16: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN CHINA (2018 - 2027)

Exhibit 17: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN CHINA (2018 - 2020)

Exhibit 18: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN CHINA (2021 - 2027)

Exhibit 19: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN JAPAN (2018 - 2027)

Exhibit 20: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN JAPAN (2018 - 2020)

Exhibit 21: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN JAPAN (2021 - 2027)

Exhibit 22: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN JAPAN (2018 - 2027)

Exhibit 23: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN JAPAN (2018 - 2020)

Exhibit 24: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN JAPAN (2021 - 2027)

Exhibit 25: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN GERMANY (2018 - 2027)

Exhibit 26: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN GERMANY (2018 - 2020)

Exhibit 27: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN GERMANY (2021 - 2027)

Exhibit 28: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN GERMANY (2018 - 2027)

Exhibit 29: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN GERMANY (2018 - 2020)

Exhibit 30: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN GERMANY (2021 - 2027)

Exhibit 31: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN UK (2018 - 2027)

Exhibit 32: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN UK (2018 - 2020)

Exhibit 33: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN UK (2021 - 2027)

Exhibit 34: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN UK (2018 - 2027)

Exhibit 35: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN UK (2018 - 2020)

Exhibit 36: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN UK (2021 - 2027)

Exhibit 37: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN FRANCE (2018 - 2027)

Exhibit 38: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN FRANCE (2018 - 2020)

Exhibit 39: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN FRANCE (2021 - 2027)

Exhibit 40: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN FRANCE (2018 - 2027)

Exhibit 41: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN FRANCE (2018 - 2020)

Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN FRANCE (2021 - 2027)

Exhibit 42: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN ITALY (2018 - 2027)

Exhibit 43: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN ITALY (2018 - 2020)

Exhibit 44: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN ITALY (2021 - 2027)

Exhibit 45: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP ITALY (2018 - 2027)

Exhibit 46: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN ITALY (2018 - 2020)

Exhibit 47: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN ITALY (2021 - 2027)

Exhibit 48: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN SPAIN (2018 - 2027)

Exhibit 49: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN SPAIN (2018 - 2020)

Exhibit 50: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN SPAIN (2021 - 2027)

Exhibit 51: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN SPAIN (2018 - 2027)

Exhibit 52: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN SPAIN (2018 - 2020)

Exhibit 53: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN SPAIN (2021 - 2027)

Exhibit 54: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 55: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN 8 MAJOR MARKETS (2018 - 2020)

Exhibit 56: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 57: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 58: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 59: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN US (2021 - 2027)

Exhibit 60: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN US (2018 - 2020)

Exhibit 61: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN US (2021 - 2027)

Exhibit 62: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN US (2021 - 2027)

Exhibit 63: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN US (2021 - 2027)

Exhibit 64: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN CHINA (2021 - 2027)

Exhibit 65: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN CHINA (2018 - 2020)

Exhibit 66: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN CHINA (2021 - 2027)

Exhibit 67: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN CHINA (2021 - 2027)

Exhibit 68: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN CHINA (2021 - 2027)

Exhibit 69: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN JAPAN (2021 - 2027)

Exhibit 70: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN JAPAN (2018 - 2020)

Exhibit 71: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN JAPAN (2021 - 2027)

Exhibit 72: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN JAPAN (2021 - 2027)

Exhibit 73: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN JAPAN (2021 - 2027)

Exhibit 74: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN GERMANY (2021 - 2027)

Exhibit 75: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN GERMANY (2018 - 2020)

Exhibit 76: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN GERMANY (2021 - 2027)

Exhibit 77: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN GERMANY (2021 - 2027)

Exhibit 78: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN GERMANY (2021 - 2027)

Exhibit 79: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN UK (2021 - 2027)

Exhibit 80: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN UK (2018 - 2020)

Exhibit 81: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN UK (2021 - 2027)

Exhibit 82: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN UK (2021 - 2027)

Exhibit 83: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN UK (2021 - 2027)

Exhibit 84: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN FRANCE (2021 - 2027)

Exhibit 85: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN FRANCE (2018 - 2020)

Exhibit 86: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN FRANCE (2021 - 2027)

Exhibit 87: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN FRANCE (2021 - 2027)

Exhibit 88: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN FRANCE (2021 - 2027)

Exhibit 89: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN ITALY (2021 - 2027)

Exhibit 90: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN ITALY (2018 - 2020)

Exhibit 91: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN ITALY (2021 - 2027)

Exhibit 92: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN ITALY (2021 - 2027)

Exhibit 93: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN ITALY (2021 - 2027)

Exhibit 94: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN SPAIN (2021 - 2027)

Exhibit 95: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN SPAIN (2018 - 2020)

Exhibit 96: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN SPAIN (2021 - 2027)

Exhibit 97: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN SPAIN (2021 - 2027)

Exhibit 98: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN SPAIN (2021 - 2027)

Exhibit 99: HEPATOCELLULAR CARCINOMA MARKETED DRUGS - AN OVERVIEW

Exhibit 100: HEPATOCELLULAR CARCINOMA MARKETED DRUGS - SUMMARY

Exhibit 101: PIPELINE DRUGS OVERVIEW IN HCC THERAPEUTICS MARKET

Exhibit 102: HCC PIPELINE DRUGS OVERVIEW BY DISEASE TYPE

Exhibit 103: HCC PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE

Exhibit 104: HCC PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION

Exhibit 105: HCC PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION

Exhibit 106: HCC PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE

Exhibit 107: HCC PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE

Exhibit 108: HCC CLINICAL TRIAL ANALYSIS SNAPSHOT

Exhibit 109: HCC CLINICAL TRIAL ANALYSIS SNAPSHOT BY RECRUITMENT STATUS

Exhibit 110: HCC CLINICAL TRIAL ANALYSIS SNAPSHOT BY PRODUCT TYPE

Exhibit 111: HCC CLINICAL TRIAL ANALYSIS SNAPSHOT BY ROUTE OF ADMINISTRATION

Exhibit 112: HCC CLINICAL TRIAL ANALYSIS SNAPSHOT BY MOLECULE TYPE

Exhibit 113: HCC CLINICAL TRIAL ANALYSIS SNAPSHOT BY GEOGRAPHY TYPE

Exhibit 114: COMPETITIVE ASSESSMENT OF HCC THERAPEUTICS MARKET

LIST OF TABLES

Table 1: KEY MARKET DRIVERS IN HCC THERAPEUTICS MARKET

Table 2: KEY MARKET CONSTRAINTS IN HCC THERAPEUTICS MARKET

Table 3: KEY MARKET TRENDS IN HCC THERAPEUTICS MARKET

Table 4: KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUGS IN HCC

Table 5: KEY REGULATORY DESIGNATIONS OF PIPELINE DRUGS IN HCC

Table 6: KEY MILESTONES IN HCC THERAPEUTICS MARKET

Table 7: KEY DEALS & COLLABORATIONS IN HCC THERAPEUTICS MARKET

Table 8: KEY INACTIVE/DISCONTINUED PRODUCTS IN HCC THERAPEUTICS MARKET

Table 9: UNMET NEEDS/STRATEGIC RECOMMENDATIONS IN HCC THERAPEUTICS MARKET